Immatics NVIMTX +2.15%60 Pretax Margin % is -758.83% as of Mar. 2026. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.57 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 946 Biotechnology companies, Immatics NV ranks worse than 72.09% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Immatics NV's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-66.78 Mil. Immatics NV's Revenue for the
three
months ended in Mar. 2026 was $8.80 Mil. Therefore, Immatics NV's pretax margin for the quarter that ended in Mar. 2026 was -758.83%.
The historical rank and industry rank for Immatics NV's Pretax Margin % or its related term are showing as below:
IMTX'
s Pretax Margin % Range Over the Past 10 Years
Min: -858.22 Med: -224.06 Max: 24.32
Current: -575.27
IMTX's Pretax Margin % is ranked worse than 72.09% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs IMTX: -575.27
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Immatics NV Pretax Margin % Related Terms
Immatics NV Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Immatics NV's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMTX vs INVA, PGEN, VIR: Pretax Margin % Comparison
For the Biotechnology subindustry, Immatics NV's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immatics NV Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immatics NV's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Immatics NV's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immatics NV (IMTX) has a Pretax Margin % of -758.83% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Immatics NV and its competitors. According to the industry distribution chart, Immatics NV ranks #682 out of 946 companies in the Biotechnology industry, placing it in the top 72.1%.
Is Immatics NV's Pretax Margin % too high?
Immatics NV's current Pretax Margin % is -758.83%. Based on the distribution chart, Immatics NV ranks #682 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's Pretax Margin % compare to INVA and PGEN?
According to the Biotechnology industry distribution chart, Immatics NV ranks #682 out of 946 companies for Pretax Margin %. This places Immatics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Immatics NV and its competitors. Immatics NV's current Pretax Margin % is -758.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.57, compared to a current price of $9.73 — trading 172.5% above its estimated fair value. The current Pretax Margin % is -758.83%. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Immatics NV (IMTX), the current Pretax Margin % is -758.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immatics NV (IMTX) Overvalued in 2026?
Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued.
The current stock price of $9.73 is trading 172.5% above its estimated GF Value™ of $3.57.
GuruFocus considers Immatics NV to be Significantly Overvalued.
Key valuation signals for IMTX:
Pretax Margin %: -758.83%
GF Value™: $3.57 vs. price of $9.73 (172.5% above fair value)
No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score
Get the complete analysis for IMTX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMTX has been successfully added to your 
